[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_96":97},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","i7snnm41vx52udqahs6k68ogc","revision",2,"title","Alterity Therapeutics 提交 6-K 文件，披露拟发行证券","originalTitle","6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)","summary","Alterity Therapeutics 向 SEC 提交 6-K 文件，列出附件“拟发行证券 - ATH 1”。该文件被纳入公司现有的 Form S-8 和 Form F-3 注册声明。","reason","source",{"_11":86,"_87":88,"_89":90,"_91":57,"_92":93,"_94":95},"links",{"_83":84,"_63":85},"publishedAt","2026-10-23T10:03:40.000Z","discoveredAt","2026-10-23T10:58:44.536Z","timelineAt","category","ai-products","tags",[81,82],"stockSymbols",[80],"score",15,"selected",false,"channel","news","story",{"_72":73,"_15":74},"x","readingMode","full","author","language","body",{"_76":-5,"_63":77,"_78":-5,"_79":40},"outline",[],"relatedStories",[75],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","f3eqrIvmLJ14",{"_72":73,"_15":74},"reportCount",3,"additionalSourceCount",0,"developmentCount","publicId","533791d1-3aaf-441c-8b4a-58f4ebd8ca58","Alterity Therapeutics提交6-K披露证券事项",{"_72":73,"_15":74},"zh","

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-163

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2026

Alterity Therapeutics Limited

(Name of Registrant)

Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (File No. 333-274816)

ALTERITY THERAPEUTICS LIMITED

(a development stage enterprise)

The following exhibits are submitted:

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

\n\t\t\t

99.1

\n\t\t\t

Proposed issue of securities - ATH

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

\n\n\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\t\t\n\t\t\t\n\t\t\t\n\t\t\t\n\t\t\n\n

	\n\t\t\t Alterity Therapeutics Limited \n\t\t\t

	\n\t\t\t By: \n\t\t\t	\n\t\t\t /s/ Julian Babarczy \n\t\t\t
		\n\t\t\t Julian Babarczy \n\t\t\t
		\n\t\t\t Chairman \n\t\t\t

Date: October 23, 2026

","zhKind","complete","ATHE","公司与财报","融资","aihot","/items/i7snnm41vx52udqahs6k68ogc","https://www.sec.gov/Archives/edgar/data/1131343/000143774926033323/0001437749-26-033323-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792972800&sig=9d173b888aad17ec","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792972800&sig=997f44534d647b46 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792972800&sig=923979fb4a1845f5 96w","changelogVersion","2026-10-01T08:00"]